NanoViricides, Inc.

As of March 31, 2026, NanoViricides, Inc. carries a market capitalization of 17.53M, placing it among publicly traded companies globally. Its enterprise value stands at 14.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NanoViricides, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of March 31, 2026, NanoViricides, Inc. has 21.65M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, NanoViricides, Inc. maintains a current ratio of 3.17, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, NanoViricides, Inc. posted a negative return on equity (ROE) of -89.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -79.91, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, NanoViricides, Inc.'s stock has gained approximately 1.63% over the past 52 weeks. The 50-day moving average sits at 1.15, while the 200-day moving average is 1.12.

Over the twelve months ended March 31, 2026, NanoViricides, Inc. generated - - in revenue and converted that into -7.00M in net income, yielding earnings per share of -0.37. EBITDA reached -6.59M, while operating income came in at -7.07M.

These figures are as of March 31, 2026. Total book value stands at 7.92M, with working capital of 2.00M providing operational flexibility.

NanoViricides, Inc. produced -6.29M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -81,765.79 in capital expenditures, free cash flow totaled -6.38M - equivalent to -0.34 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -41.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -39.67, meaning NanoViricides, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

NanoViricides, Inc.'s most recent stock split took place on September 24, 2019 with a 20:1 split ratio.

As of March 31, 2026, NanoViricides, Inc. has an Altman Z-Score of -12.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.